Table 2 Patient characteristics
No | Age | Sex | Comorbidities | Vaccination frequency | Initial spike-specific antibody (U/ml) | Viral load Initial GA (copy/µL) (Days after onset) | Viral load Subsequent GA (copy/µL) (Days after onset) | Current immunosuppressive drug | Severity of COVID-19 |
|---|---|---|---|---|---|---|---|---|---|
1 | 81 | Female | DLBCL | 3 | 61.9 | 387834 (2) | 318187 (31) 218663 (51) | Rituximab Obinutuzumab Bendamustine | Severe |
2 | 71 | Male | Kidney transplantation | 3 | <0.4 | 1351495 (9) | 1466 (24) | Tacrolimus Mycophenolate mofetil Methylprednisolone | Critical |
3 | 66 | Female | Kidney transplantation | 3 |  < 0.4 | 8570 (1) | 7670 (21) | Tacrolimus Mycophenolate mofetil Methylprednisolone | Moderate |
4 | 44 | Male | Kidney transplantation | 3 | <0.4 | 135269 (2) | 21798 (19) | Tacrolimus Mycophenolate mofetil Methylprednisolone | Moderate |
5 | 80 | Female | DLBCL | 2 | 14.9 | 2839493 (0) | 5853 (13) 2130 (28) | Polatuzumab vedotin Rituximab Bendamustine | Moderate |
6 | 35 | Female | Malignant lymphoma | none | 20763 | 2420,183 (3) | 627186 (10) | Unknown | Moderate |
7 | 74 | Male | Multiple myeloma | none | 1.73 | 5425 (18) | 708919 (32) | Pomalidomide Bortezomib | Severe |
8 | 78 | Male | Follicular lymphoma | 5 | 1740 | 34647 (0) | 165652 (18) | Polatuzumab vedotin Rituximab Bendamustine | Critical |
9 | 70 | Female | Autoimmune hepatitis | none |  < 0.4 | 704487 (6) | 54144 (29) | Rituximab Prednisolone | Severe |
10 | 80 | Male | Multiple myeloma | 4 |  < 0.4 | 22116 (0) | 2049 (33) 32566 (46) | Pomalidomide Ixazomib | Severe |
11 | 49 | Female | Kidney transplantation | 3 | <0.4 | 5578198 (2) | 842 (19) | Mycophenolate mofetil Cyclosporine | Moderate |
12 | 79 | Female | Follicular lymphoma | 3 | 8945 | Â | 513 (90) | Rituximab Obinutuzumab Bendamustine | Severe |
13 | 54 | Male | Follicular lymphoma | 3 | <0.4 | Â | 52051 (55) | Rituximab Obinutuzumab Bendamustine | Severe |
14 | 81 | Male | Follicular lymphoma | 2 | 2814 | Â | 537627 (74) | Rituximab Obinutuzumab Bendamustine | Severe |
15 | 81 | Male | MALT lymphoma | 4 | 84.5 | Â | 31406 (173) | Rituximab Bendamustine | Critical |
16 | 54 | Female | Follicular lymphoma | none | 2153 | Â | 619 (125) | Obinutuzumab Bendamustine | Severe |
17 | 82 | Male | Kidney transplantation | 4 | <0.4 | Â | 16042 (17) | Tacrolimus Mycophenolate mofetil Prednisolone | Critical |